<DOC>
	<DOCNO>NCT00992420</DOCNO>
	<brief_summary>This study sub-study GRAVITAS ( clinicaltrials.gov identifier NCT00645918 ) . The purpose study ass gene influence residual platelet reactivity standard dose clopidogrel therapy , also determine whether certain gene influence incremental change platelet reactivity high-dose clopidogrel maintenance dose patient high residual platelet reactivity standard dosing .</brief_summary>
	<brief_title>Genotype Information Functional Testing Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients meet inclusion criterion GRAVITAS undergo VerifyNow blood sample VerifyNow P2Y12 platelet function test IVRS entry GRAVITAS randomization/selection determination See GRAVITAS trial ( ClinicalTrials.gov identifier : NCT00645918 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>thienopyridine</keyword>
	<keyword>platelet</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>platelet function test</keyword>
	<keyword>platelet</keyword>
	<keyword>gene</keyword>
	<keyword>cytochrome P450</keyword>
	<keyword>single nucleotide polymorphism</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
</DOC>